Physician profile
Michael S Mall
NPI 1972513091
$2,581.05
in general payments reported to CMS, 2019-2025
24 companies · $93.70 in 2025
The $93.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $430 · 2021: $271 · 2022: $166 · 2023: $30.68 · 2024: $131 · 2025: $93.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $614.02 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $364.25 | 2019-2021 | |
| Merz North America, INC. | $305.45 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.52 | 2019-2024 | Xifaxan |
| Amgen INC. | $187.23 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $132.69 | 2019-2020 | |
| Astellas Pharma US INC | $113.63 | 2019-2025 | Veozah |
| Lilly USA, LLC | $96.70 | 2020-2025 | Mounjaro, Zepbound |
| Genentech USA, INC. | $79.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $61.54 | 2019 | |
| Novo Nordisk INC | $61.22 | 2019-2020 | |
| Exact Sciences Corporation | $58.35 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $40.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.95 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $38.49 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.37 | 2019 | |
| Allergan, INC. | $33.58 | 2019 | |
| Smith+Nephew, INC. | $28.64 | 2025 | Grafix Pl |
| Depuy Synthes Sales INC. | $22.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.44 | 2020 | |
| Strongbridge US INC. | $14.09 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.06 | 2019 | |
| Ethicon US, LLC | $12.65 | 2019 | |
| Medtronic Minimed, INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.